Yahoo
Shanghai - Delayed Quote CNY

Shanghai Pharmaceuticals Holding Co., Ltd (601607.SS)

16.52 +0.09 (+0.55%)
At close: October 30 at 3:00:02 PM GMT+8
View in AlphaSpace Currency in CNY All numbers in thousands
Financial statements are getting an update on November 9
Preview it now to see what’s changing.
Learn more
Breakdown
TTM
12/31/2025
12/31/2024
12/31/2023
12/31/2022
Total Revenue
291,471,349.87
283,579,600.56
275,250,934.89
260,295,088.94
231,981,299.76
Cost of Revenue
260,009,996.85
253,163,120.90
244,619,261.05
228,966,947
201,494,923.09
Gross Profit
31,461,353.02
30,416,479.66
30,631,673.84
31,328,141.94
30,486,376.68
Operating Expense
21,402,871.93
21,133,323.51
20,941,761.56
21,762,997.48
21,705,375.12
Operating Income
10,058,481.10
9,283,156.16
9,689,912.28
9,565,144.47
8,781,001.55
Net Non Operating Interest Income Expense
-1,244,604.43
-1,345,181.22
-1,406,986.03
-1,497,164.21
-1,334,703.61
Pretax Income
9,077,830.93
9,819,804.52
8,020,006.54
7,054,296.74
8,808,353.28
Tax Provision
2,323,930.83
2,846,086.84
2,149,995.23
1,887,726.45
1,816,338.51
Net Income Common Stockholders
5,163,456.24
5,724,557.51
4,552,528.44
3,767,999.58
5,617,152
Basic EPS
1.39
1.54
1.23
1.02
1.61
Diluted EPS
1.39
1.54
1.23
1.02
1.61
Basic Average Shares
3,713,820.17
3,717,245.14
3,701,242.63
3,694,117.24
3,488,914.29
Diluted Average Shares
3,713,820.17
3,717,245.14
3,701,242.63
3,694,117.24
3,488,914.29
Total Operating Income as Reported
9,177,628.30
9,942,085.63
8,140,712.95
7,667,234.70
9,014,650.39
Rent Expense Supplemental
209,946.59
229,845.43
225,264.32
259,575.83
261,645.83
Total Expenses
281,412,868.78
274,296,444.41
265,561,022.61
250,729,944.48
223,200,298.21
Net Income from Continuing & Discontinued Operation
5,163,456.24
5,724,557.51
4,552,528.44
3,767,999.58
5,617,152
Normalized Income
5,555,766.04
6,617,536.90
4,997,122.93
4,157,364.12
4,876,371.06
Interest Income
271,969.47
404,967
522,385.72
461,833.29
438,297.67
Interest Expense
1,448,789.99
1,685,890.51
1,856,737.43
1,884,984.09
1,689,278.92
Net Interest Income
-1,244,604.43
-1,345,181.22
-1,406,986.03
-1,497,164.21
-1,334,703.61
EBIT
10,526,620.92
11,505,695.02
9,876,743.97
8,939,280.83
10,497,632.20
EBITDA
10,526,620.92
14,367,815.98
12,295,542.75
11,126,411.65
12,720,073.07
Reconciled Cost of Revenue
260,009,996.85
253,163,120.90
244,619,261.05
228,966,947
201,494,923.09
Reconciled Depreciation
2,622,325.33
2,862,120.95
2,418,798.78
2,187,130.82
2,222,440.86
Net Income from Continuing Operation Net Minority Interest
5,163,456.24
5,724,557.51
4,552,528.44
3,767,999.58
5,617,152
Total Unusual Items Excluding Goodwill
-527,298.60
-1,257,418.71
-607,435.07
-531,627.92
933,216.03
Total Unusual Items
-527,298.60
-1,257,418.71
-607,435.07
-531,627.92
933,216.03
Normalized EBITDA
11,053,919.51
15,625,234.69
12,902,977.83
11,658,039.57
11,786,857.03
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
-134,988.80
-364,439.32
-162,840.58
-142,263.38
192,435.09
12/31/2022 - 3/24/1994

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

Mobilize your Website
View Site in Mobile | Classic
Share by: